Protective effect of gallic acid on alloxan-induced oxidative stress and osmotic fragility in rats

Human and Experimental Toxicology - Tập 33 Số 6 - Trang 638-649 - 2014
Kunka Mohanram Ramkumar1, RS Vijayakumar2, Pachamuthu Vanitha1, Natarajan Suganya1, C. Manjula3, P. Rajaguru3, S Sivasubramanian4, P. Gunasekaran4
1SRM Research Institute, SRM University, Kattankulathur, Chennai, Tamil Nadu, India
2Institute of Biotechnology and Pharmaceutical Research, The National Health Research Institutes, Zhunan, Miaoli County, Taiwan.
3Department of Biotechnology, Anna University, BIT-Campus, Tiruchirappalli, Tamil Nadu, India
4King Institute of Preventive Medicine and Research, Guindy, Chennai, Tamil Nadu, India

Tóm tắt

In the present study, we investigated the antioxidant effect of gallic acid (GA) on membrane lipid peroxidation and osmotic fragility in alloxan-induced diabetic Wistar rats. GA was administered orally at doses of 5, 10, and 20 mg/kg body weight for 45 days, after which liver and kidney tissues were analyzed for the degree of lipid peroxidation, reduced glutathione, and the activities of antioxidants such as catalase, superoxide dismutase, and glutathione peroxidase. Administration of GA to alloxan-induced diabetic rats reduced the blood glucose level with an increase in the level of insulin. Liver and kidney tissues from diabetic animals exhibited disturbances in antioxidant defense compared with normal rats. GA at a dose of 20 mg/kg b.w. showed a significant effect than that of the other doses. In addition, the results revealed that GA protected the integrity of erythrocyte membrane in diabetic rats as demonstrated by lower percentage of hemolysis and resistance to hydrogen peroxide-induced peroxidation. The anti-hyperglycemic activity of GA in alloxan-induced diabetic rats was also comparable with glibenclamide, a reference drug. These results suggest that GA could provide a beneficial effect on diabetes by decreasing oxidative stress-related diabetic complications.

Từ khóa


Tài liệu tham khảo

10.1016/j.diabres.2011.10.029

10.1023/A:1006834922035

10.2337/diab.40.4.405

10.1016/S0026-0495(00)80082-7

10.1097/00075197-200209000-00016

10.1111/j.1523-1755.2004.00491.x

10.2337/diabetes.54.6.1615

10.2337/diabetes.54.suppl_2.S97

10.1016/0891-5849(96)02051-5

10.2337/diab.27.9.895

10.1016/S0378-8741(03)00036-9

10.1016/S0031-9422(00)00456-8

10.1016/S0378-8741(02)00059-4

Malviya N, 2010, Acta Pol Pharm, 67, 113

10.1177/014572179802400210

10.1007/s11655-011-0810-3

10.1021/jf061554+

10.1006/bbrc.1994.2544

10.1248/bpb.23.1153

10.1248/bpb.30.1052

Faried A, 2007, Int J Oncol, 30, 605

10.1039/np9941100041

10.1016/j.cbi.2008.12.012

10.1093/jn/131.4.1207

10.1016/S0278-6915(01)00022-9

Soto C, 1994, Arch Med Res, 25, 377

10.1007/s00125-007-0886-7

10.1002/jbt.20360

10.1016/S2221-1691(11)60085-3

10.1136/jcp.20.6.910

10.1067/mob.2000.105391

10.1111/j.1432-1033.1968.tb00428.x

10.1016/0003-2697(72)90132-7

Kakkar P, 1984, Indian J Biochem Biophys, 21, 130

10.1126/science.179.4073.588

10.1038/202904a0

10.1182/blood.V59.6.1141.1141

10.1016/0009-8981(85)90320-1

Pal SK, 2003, Asian Pac J Cancer Prev, 4, 281

10.1080/10408398.2010.499017

10.1039/b514294f

10.2174/1389200033489479

10.1021/jf000089s

10.4103/0974-8490.89743

10.2337/diab.40.6.701

10.1016/S0195-5616(95)50058-0

10.4314/eamj.v78i8.8998

10.1016/0009-3084(87)90049-1

10.1007/s12291-008-0050-2

10.12816/0003082

10.1113/jphysiol.2007.135871

Saba AB, 2010, Afr Health Sci, 10, 276

10.1089/ars.2006.1465

10.1016/j.cellsig.2011.06.001

10.1159/000257480

10.1080/14786410902726126

10.1515/cclm.2011.250

10.3164/jcbn.11-014FR

10.1002/(SICI)1096-9136(199612)13:12<1044::AID-DIA273>3.0.CO;2-#

10.1016/0968-0004(90)90206-Q

10.1016/0891-5849(93)90512-S

10.1016/S0753-3322(03)00043-X

10.1016/S0021-9258(19)30085-7

10.3109/00313028309085173

10.2337/diacare.23.8.1182

10.2337/diab.38.12.1539

Thông tin
Thông tin xuất bản

Human and Experimental Toxicology

Tập 33 Số 6

638-649

Thông tin tác giả